These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28619439)

  • 1. Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
    Susser S; Dietz J; Schlevogt B; Zuckerman E; Barak M; Piazzolla V; Howe A; Hinrichsen H; Passmann S; Daniel R; Cornberg M; Mangia A; Zeuzem S; Sarrazin C
    J Hepatol; 2017 Oct; 67(4):680-686. PubMed ID: 28619439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
    Mangia A; Susser S; Piazzolla V; Agostinacchio E; De Stefano G; Palmieri V; Spinzi G; Carraturo I; Potenza D; Losappio R; Arleo A; Miscio M; Santoro R; Sarrazin C; Copetti M
    J Hepatol; 2017 Apr; 66(4):711-717. PubMed ID: 27965158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.
    Paolucci S; Premoli M; Ludovisi S; Mondelli MU; Baldanti F
    Antivir Ther; 2017; 22(4):365-368. PubMed ID: 28085002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia.
    Zakalashvili M; Zarkua J; Weizenegger M; Bartel J; Raabe M; Zangurashvili L; Kankia N; Jashiashvili N; Lomidze M; Telia T; Kerashvili V; Zhamutashvili M; Abramishvili N; Hedskog C; Chodavarapu K; Brainard DM; McHutchison JG; Mo H; Svarovskaia E; Gish RG; Rtskhiladze I; Metreveli D
    Liver Int; 2018 Mar; 38(3):451-457. PubMed ID: 28782185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.
    Okada M; Hai H; Tamori A; Uchida-Kobayashi S; Enomoto M; Kumada H; Kawada N
    Clin J Gastroenterol; 2019 Jun; 12(3):213-217. PubMed ID: 30446954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed Hepatitis C infection: a case report.
    Morel V; Descamps V; François C; Fournier C; Brochot E; Capron D; Duverlie G; Castelain S
    J Clin Virol; 2010 Apr; 47(4):382-6. PubMed ID: 20153975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
    Sarrazin C; Isakov V; Svarovskaia ES; Hedskog C; Martin R; Chodavarapu K; Brainard DM; Miller MD; Mo H; Molina JM; Sulkowski MS
    Clin Infect Dis; 2017 Jan; 64(1):44-52. PubMed ID: 27737953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b].
    Jin YJ; Park YK; Yun GJ; Lee HC; Jeong SH; Kim GM; Lim YS; Chung YH; Lee YS; Suh DJ
    Korean J Hepatol; 2010 Jun; 16(2):158-67. PubMed ID: 20606500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection.
    Mettikanont P; Bunchorntavakul C; Reddy KR
    Aliment Pharmacol Ther; 2019 Mar; 49(5):492-505. PubMed ID: 30687952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China.
    Jia Y; Yue W; Gao Q; Tao R; Zhang Y; Fu X; Liu Y; Liu L; Feng Y; Xia X
    Microbiol Spectr; 2021 Sep; 9(1):e0029721. PubMed ID: 34479413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
    N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.
    Welzel TM; Bhardwaj N; Hedskog C; Chodavarapu K; Camus G; McNally J; Brainard D; Miller MD; Mo H; Svarovskaia E; Jacobson I; Zeuzem S; Agarwal K
    J Hepatol; 2017 Aug; 67(2):224-236. PubMed ID: 28343981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prevalence of Mixed Hepatitis C Virus Genotype Infection and Its Effect on the Response to Direct-Acting Antivirals Therapy.
    Hayashi K; Tachi K; Shimizu Y; Nagano K; Ishizu Y; Kuzuya T; Honda T; Ishigami M; Hirooka Y; Hattori M; Goto H
    Intervirology; 2019; 62(1):23-29. PubMed ID: 31207601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of Hepatitis C Virus Genotype Recombinant Forms 2k/1b in Georgia.
    Zakalashvili M; Weizenegger M; Bartel J; Markowski M; Zarqua J; Kavsadze S; Kvatadze K; Basheleishvili G; Phirtskhalaishvili T; Dzagania T; Zangurashvili L; Kankia N; Jashiashvili N; Lomidze M; Telia T; Kerashvili V; Zhamutashvili M; Abramishvili N; Rtskhiladze I; Metreveli D
    Clin Lab; 2016 Jul; 62(7):1347-1351. PubMed ID: 28164650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b.
    Kurbanov F; Tanaka Y; Chub E; Maruyama I; Azlarova A; Kamitsukasa H; Ohno T; Bonetto S; Moreau I; Fanning LJ; Legrand-Abravanel F; Izopet J; Naoumov N; Shimada T; Netesov S; Mizokami M
    J Infect Dis; 2008 Nov; 198(10):1448-56. PubMed ID: 18928375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis.
    Berden FA; Aaldering BR; Groenewoud H; IntHout J; Kievit W; Drenth JP
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):349-359. PubMed ID: 27840182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.